Literature DB >> 3973650

Prognostic groups for management of localized Hodgkin's disease.

S B Sutcliffe, M K Gospodarowicz, D E Bergsagel, R S Bush, R E Alison, H A Bean, T C Brown, T Chua, R M Clark, J E Curtis.   

Abstract

Two hundred fifty-two patients receiving radical irradiation for clinical stages I and II Hodgkin's disease between 1968 to 1977 had an actuarial ten-year survival rate of 78% and a relapse-free rate of 61%. Sixty-seven patients receiving chemotherapy followed by radiation had a 78% survival rate and a 63% relapse-free rate. Independent prognostic factors for survival and relapse were age, stage, and histology. Disease bulk was predictive only of relapse. Neither site of presentation above or below the diaphragm nor presence of mediastinal involvement was predictive for survival or relapse; however, patients with large mediastinal masses (greater than or equal to 10 cm absolute diameter) had a significantly higher intrathoracic failure rate with conventional mantle irradiation. Analysis of failure, according to age, clinical stage, and histologic type, showed three groups of patients defined according to the risk of relapse with radiation therapy: those with isolated upper cervical stage IA disease (group 1, relapse rate 8%), younger patients with localized stages I and II disease of favorable histologic type (group 2, relapse rate 35%), and older patients with extensive or symptomatic stages I and II disease of less favorable histologic type (group 3, relapse rate 70%). Subsequent analysis of radiation treatment volume indicates that the use of upper abdominal irradiation for patients in group No. 2 could yield results equivalent to those achieved with radiation therapy for surgically staged patients.

Entities:  

Mesh:

Year:  1985        PMID: 3973650     DOI: 10.1200/JCO.1985.3.3.393

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  7 in total

Review 1.  Current therapies in Hodgkin's disease.

Authors:  K E Kogel; J W Sweetenham
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-30       Impact factor: 9.236

2.  Radiation therapy alone versus radiation therapy and chemotherapy in the management of Hodgkin's disease.

Authors:  L D Glenn; P P Kumar
Journal:  J Natl Med Assoc       Date:  1990-02       Impact factor: 1.798

Review 3.  Early stage Hodgkin's disease in adults: which is the correct treatment?

Authors:  M Brada
Journal:  Postgrad Med J       Date:  1989-11       Impact factor: 2.401

Review 4.  Early-stage Hodgkin's disease: current approaches to treatment.

Authors:  J J Rusthoven; R MacKenzie
Journal:  Can Med Assoc J       Date:  1985-08-01       Impact factor: 8.262

Review 5.  Extended-field isocentric irradiation for Hodgkin's disease.

Authors:  P P Kumar; R R Good; E O Jones; J E Somers; B E McAnulty; G F McCaul; S S Rogers; M A Reeves; C K Sanders
Journal:  J Natl Med Assoc       Date:  1987-09       Impact factor: 1.798

6.  Radiotherapy for stage I Hodgkin's disease: 20 years experience at St Bartholomew's Hospital.

Authors:  T S Ganesan; P F Wrigley; P A Murray; A G Stansfeld; A J d'Ardenne; S Arnott; A Jones; W S Shand; J S Malpas; T A Lister
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

7.  Changing patterns of relapse in Hodgkin's disease.

Authors:  G Duchesne; J Crow; S Ashley; M Brada; A Horwich
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.